Single Cell Characterization of Prostate Cancer-Circulating Tumor Cells

2013 ◽  
Author(s):  
James D. Brooks
Keyword(s):  
Prostate Cancer ◽  
Single Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Characterization

Abstract LB-236: Genomic characterization of circulating tumor cells in de novo metastatic prostate cancer

2019 ◽  
Author(s):  
Shoujie Chai ◽  
Paymaneh D. Malihi ◽  
Ana M. Apariciop ◽  
Brian F. Chapin ◽  
Matthew Lin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Metastatic Prostate Cancer ◽  
De Novo ◽  
Genomic Characterization

Morphologic and genomic characterization of circulating tumor cells in patients with metastatic colorectal cancer treated with combinational treatment of andecaliximab, bevacizumab and chemotherapy.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14753-e14753
Author(s):  
Stephanie Shishido ◽  
Peter Kuhn
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Single Cell ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Liquid Biopsy ◽  
Clinical Decision Making ◽  
Line Therapy ◽  
Combinational Treatment

e14753 Background: The liquid biopsy is a noninvasive route to evaluate circulating tumor cells (CTCs) during the course of treatment to gain understanding of tumor biology, with potential prognostic utility. CTCs could serve as a predictive biomarker while aiding in the identification of resistance mechanisms to treatment through single cell genomic and proteomic analysis providing a longitudinal snapshots of tumor heterogeneity. Methods: Through the use of the high definition single cell assay (HD-SCA) workflow, we characterized the rare circulating cells to determine prognostic value of the liquid biopsy in monitoring the efficacy of andecaliximab in a combinational treatment as 1st or 2nd line therapy in patients with metastatic colorectal cancer (mCRC). 174 samples from 95 patients were analyzed to determine the significance of CTCs during treatment. Results: HD-CTCs were detected in 31% of samples, with 41 (43%) patients being CTC positive in at least 1 timepoint during the study. Patients receiving 1st line therapy presented with a median of 0 (range 0-346.04) and a mean of 9.49 (±14.06) HD-CTC/mL at baseline (BL). At initiation of 2nd line therapy, patients presented with a median of 0 HD-CTC/mL (range 0-277.37) and a mean of 10.94 (±15.32). There was no association between BL HD-CTC/mL and response, but for the 20 patients with > 1 HD-CTC at BL, there was a trend toward response for higher HD-CTC/mL (non-response: mean 2.8, n = 12; response: mean 89.7, n = 8; p = .04). The 3 patients with > 10 HD-CTC/mL at BL had undetectable HD-CTC on-treatment, which accompanied radiologic partial response; however, the 2 patients with complete radiological response had no HD-CTC detected at BL. In case studies, treatment pressure led to an observable change in HD-CTC morphology and genomic instability (single cell CNV analysis), suggesting these parameters may inform prognosis. Conclusions: Characterization of CTCs from patients with mCRC is feasible and may provide prognostic information to guide clinical decision making. Further evaluation of CTCs for pharmacodynamics and clinical monitoring in patients with mCRC is warranted.

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

2009 ◽  
Vol 69 (7) ◽  
pp. 2912-2918 ◽  
Author(s):  
Gerhardt Attard ◽  
Joost F. Swennenhuis ◽  
David Olmos ◽  
Alison H.M. Reid ◽  
Elaine Vickers ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Pten Gene ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant ◽  
Gene Status

scholarly journals The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer

2015 ◽  
Vol 22 (6) ◽  
pp. 1510-1519 ◽  
Author(s):  
Himisha Beltran ◽  
Adam Jendrisak ◽  
Mark Landers ◽  
Juan Miguel Mosquera ◽  
Myriam Kossai ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Partial Characterization ◽  
Neuroendocrine Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document